射频消融联合支气管动脉灌注化疗在晚期非小细胞肺癌治疗中的应用  

Clinical value of radiofrequency ablation combined with bronchial artery infusion chemotherapy for the late non-small cell lung cancer

作　　者：孙一[1] 董勇[1] 肖鹏[1] 刘勤发[1] 

机构地区：[1]广东省东莞市石龙人民医院,东莞市523321

出　　处：《微创医学》2009年第2期123-125,共3页Journal of Minimally Invasive Medicine

基　　金：广东省东莞市科技局科研课题(编号:2007105150041)

摘　　要：目的研究射频消融联合支气管动脉灌注化疗在晚期非小细胞肺癌治疗中的应用价值。方法对观察组32例晚期非小细胞肺癌患者在螺旋CT定位引导下行射频消融治疗,一周后采用含顺铂的方案(紫杉醇+DDP、吉西他滨+DDP)进行支气管动脉灌注化疗,灌注治疗1～3次;选择同期接受相同化疗方案进行全身化疗的晚期非小细胞肺癌患者40例为对照组,全身化疗2～4次。比较两组的近期疗效、生存期及毒副作用。结果观察组的近期疗效(CR+PR)为78.1%对照组为37.5%,观察组和对照组有显著性差异(P<0.01)。随访6、12、24个月生存率,观察组为93.8%、75%和9.4%,对照组为67.5%、45%和2.5%,观察组明显优于对照组(P<0.01)。两组毒副作用无显著性差异(P>0.05)。结论射频消融联合支气管动脉灌注化疗是治疗晚期非小细胞肺癌的一种安全有效的方法。Objective To evaluate the clinical value of radiofrequency ablation （RFA） combined with bronchial artery inthsion chemotherapy （BAI） for the non-small cell lung cancer （NSCLC）. Method 32 patients were randomly assigned as the observation group and 40 patients as the matched group. The patients in observation group were treated by RFA under the guidance of helix CT, and added with BAI （ cisplatin solution） for 1 - 3 times one week after. The patients in matched group were treated by the chemotherapy with the same chemo solution, and chemotherapy period were repeated 2 - 4 times. The recent curative effect, survival period, and side effects of the two groups were compared. Result The recent curative effect rate （ CR ＋ PR） of observation group was 78.1%, and was 37.5% of the matched group, the difference between observation group and matched group were statistically significant（ P 〈 0.01 ）. The survival rates of 6,12 ,and 24 months in the observation group were 93.8%, 75%, 9.4%, respectively, compared with 67.5%, 45%, and 2. 5% in the matched group ,respectively （P〈0.01）. The side effect difference between two groups were not statistically significant（P〉0.05）. Conclusion RFA combined with BAI is a safe and effective treatment for the late NSCLS.

关 键 词：射频消融 支气管动脉灌注化疗 肺癌 

分 类 号：R734.2[医药卫生—肿瘤]